FDA grants BioSante Orphan Drug designation for Melanoma Cancer Vaccine

[News]

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for its Melanoma Cancer Vaccine in the treatment of stage IIb to IV melanoma, from the FDA's Office of Orphan Products Development. Melanoma is the most deadly form of skin cancer.

More... (http://www.news-medical.net/news/20110125/FDA-grants-BioSante-Orphan-Drug-designation-for-Melanoma-Cancer-Vaccine.aspx)